Draft

21  COPD

21.1 What this covers

  • Inhalers
  • Triple Inhalers
  • this is advantageous due to increased risk of severe pneumonia

21.2 Learning objectives

  • Inhalers
  • Triple Inhalers
  • this is advantageous due to increased risk of severe pneumonia
  • example of Pharmd led de-prescribing initiative: https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202007-871RL

21.3 Bottom line / summary

  • No increase in exacerbation risk for patients stable on triple inhalers (who do not have asthma or eosinophils over 300) to take off the ICS
  • this is advantageous due to increased risk of severe pneumonia
  • example of Pharmd led de-prescribing initiative: https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202007-871RL

21.4 Approach

  1. this is advantageous due to increased risk of severe pneumonia
  2. example of Pharmd led de-prescribing initiative: https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202007-871RL
  3. COPD

21.5 Red flags / when to escalate

  • TODO: List red flags that require urgent escalation.

21.6 Common pitfalls

  • No increase in exacerbation risk for patients stable on triple inhalers (who do not have asthma or eosinophils over 300) to take off the ICS

21.7 References

  • https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202007-871RL

21.8 Source notes

21.8.1 COPD

22 COPD

22.1 Inhalers

22.1.1 Triple Inhalers

No increase in exacerbation risk for patients stable on triple inhalers (who do not have asthma or eosinophils over 300) to take off the ICS

  • this is advantageous due to increased risk of severe pneumonia
  • example of Pharmd led de-prescribing initiative: https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202007-871RL

22.2 Source materials